Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1

Journal of Allergy and Clinical Immunology

Volumn 134, Issue 1, 2014, Pages 12-19

  Siliciano, Janet D ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

antiretroviral therapy; cure; eradication; HIV; latency; reservoir; stem cell transplantation

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; MYELOABLATIVE AGENT;

CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; VIRAL CLEARANCE; ADULT; COMPLICATION; DEFICIENCY; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; NEWBORN; PATHOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MYELOABLATIVE AGONISTS; RECEPTORS, CCR5; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84903615913     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.05.026     Document Type: Review

References (78)

1. M. Piatak Jr., M.S. Saag, L.C. Yang, S.J. Clark, J.C. Kappes, and K.C. Luk et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR Science 259 1993 1749 1754
2. G. Doitsh, N.L. Galloway, X. Geng, Z. Yang, K.M. Monroe, and O. Zepeda et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection Nature 505 2014 509 514
3. B.L. Jilek, M. Zarr, M.E. Sampah, S.A. Rabi, C.K. Bullen, and J. Lai et al. A quantitative basis for antiretroviral therapy for HIV-1 infection Nat Med 18 2012 446 451
4. S.M. Hammer, K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, and J.S. Currier et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS clinical trials group 320 study team N Engl J Med 337 1997 725 733
5. R.M. Gulick, J.W. Mellors, D. Havlir, J.J. Eron, C. Gonzalez, and D. McMahon et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy N Engl J Med 337 1997 734 739
6. A.S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, and K. Saksela et al. Decay characteristics of HIV-1-infected compartments during combination therapy Nature 387 1997 188 191
7. R.T. Davey Jr., N. Bhat, C. Yoder, T.W. Chun, J.A. Metcalf, and R. Dewar et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression Proc Natl Acad Sci U S A 96 1999 15109 15114
8. T.W. Chun, D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R.F. Siliciano In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency Nat Med 1 1995 1284 1290
9. T.W. Chun, L. Carruth, D. Finzi, X. Shen, J.A. DiGiuseppe, and H. Taylor et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 1997 183 188
10. D.D. Richman, D.M. Margolis, M. Delaney, W.C. Greene, D. Hazuda, and R.J. Pomerantz The challenge of finding a cure for HIV infection Science 323 2009 1304 1307
11. E. Eisele, and R.F. Siliciano Redefining the viral reservoirs that prevent HIV-1 eradication Immunity 37 2012 377 388
12. G. Hutter, D. Nowak, M. Mossner, S. Ganepola, A. Mussig, and K. Allers et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N Engl J Med 360 2009 692 698
13. S.A. Yukl, E. Boritz, M. Busch, C. Bentsen, T.W. Chun, and D. Douek et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient PLoS Pathog 9 2013 e1003347
14. D. Persaud, H. Gay, C. Ziemniak, Y.H. Chen, M. Piatak Jr., and T.W. Chun et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant N Engl J Med 369 2013 1828 1835
15. Persaud D, Deveikis A, Gay H, Batra J, Chen T, Michalik DE, et al. Very early combination antiretroviral therapy in perinatal HIV infection: two case studies. Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 5, 2014; Boston, Mass.
16. T.J. Henrich, Z. Hu, J.Z. Li, G. Sciaranghella, M.P. Busch, and S.M. Keating et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation J Infect Dis 207 2013 1694 1702
17. Henrich TJ, Hanhauser E, Sirignano MN, Li JZ, Lichterfeld M, Marty FM, et al. HIV-1 rebound following allogeneic stem cell transplantation and treatment interruption. Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 6, 2014; Boston, Mass.
18. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
19. L. Shen, S. Peterson, A.R. Sedaghat, M.A. McMahon, M. Callender, and H. Zhang et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs Nat Med 14 2008 762 766
20. G. Nabel, and D. Baltimore An inducible transcription factor activates expression of human immunodeficiency virus in T cells Nature 326 1987 711 713
21. E. Bohnlein, J.W. Lowenthal, M. Siekevitz, D.W. Ballard, B.R. Franza, and W.C. Greene The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV Cell 53 1988 827 836
22. C.H. Herrmann, and A.P. Rice Lentivirus tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a tat cofactor J Virol 69 1995 1612 1620
23. B.M. Peterlin, and D.H. Price Controlling the elongation phase of transcription with P-TEFb Mol Cell 23 2006 297 305
24. B. Descours, A. Cribier, C. Chable-Bessia, D. Ayinde, G. Rice, and Y. Crow et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells Retrovirology 9 2012 87
25. H.M. Baldauf, X. Pan, E. Erikson, S. Schmidt, W. Daddacha, and M. Burggraf et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells Nat Med 18 2012 1682 1687
26. D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, C. Buck, and R.E. Chaisson et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1997 1295 1300
27. J.D. Siliciano, and R.F. Siliciano Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals Methods Mol Biol 304 2005 3 15
28. J.D. Siliciano, J. Kajdas, D. Finzi, T.C. Quinn, K. Chadwick, and J.B. Margolick et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells Nat Med 9 2003 727 728
29. M.C. Strain, H.F. Gunthard, D.V. Havlir, C.C. Ignacio, D.M. Smith, and A.J. Leigh-Brown et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence Proc Natl Acad Sci U S A 100 2003 4819 4824
30. M. Dean, M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, and R. Allikmets et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia cohort study, San Francisco city cohort, ALIVE study Science 273 1996 1856 1862
31. D.L. Farber, N.A. Yudanin, and N.P. Restifo Human memory T cells: generation, compartmentalization and homeostasis Nat Rev Immunol 14 2014 24 35
32. N. Chomont, M. El-Far, P. Ancuta, L. Trautmann, F.A. Procopio, and B. Yassine-Diab et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation Nat Med 15 2009 893 900
33. M.J. Buzon, H. Sun, C. Li, A. Shaw, K. Seiss, and Z. Ouyang et al. HIV-1 persistence in CD4(+) T cells with stem cell-like properties Nat Med 20 2014 139 142
34. J.M. Brenchley, B.J. Hill, D.R. Ambrozak, D.A. Price, F.J. Guenaga, and J.P. Casazza et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: Implications for HIV pathogenesis J Virol 78 2004 1160 1168
35. T. Pierson, T.L. Hoffman, J. Blankson, D. Finzi, K. Chadwick, and J.B. Margolick et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1 J Virol 74 2000 7824 7833
36. L. Josefsson, S. von Stockenstrom, N.R. Faria, E. Sinclair, P. Bacchetti, and M. Killian et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time Proc Natl Acad Sci U S A 110 2013 E4987 E4996
37. T.W. Chun, D. Engel, S.B. Mizell, C.W. Hallahan, M. Fischette, and S. Park et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy Nat Med 5 1999 651 655
38. J.M. Prins, S. Jurriaans, R.M. van Praag, H. Blaak, R. van Rij, and P.T. Schellekens et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy AIDS 13 1999 2405 2410
39. J. Kulkosky, G. Nunnari, M. Otero, S. Calarota, G. Dornadula, and H. Zhang et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy J Infect Dis 186 2002 1403 1411
40. A. Jordan, D. Bisgrove, and E. Verdin HIV reproducibly establishes a latent infection after acute infection of T cells in vitro EMBO J 22 2003 1868 1877
41. G.K. Sahu, K. Lee, J. Ji, V. Braciale, S. Baron, and M.W. Cloyd A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes Virology 355 2006 127 137
42. B. Burke, H.J. Brown, M.D. Marsden, G. Bristol, D.N. Vatakis, and J.A. Zack Primary cell model for activation-inducible human immunodeficiency virus J Virol 81 2007 7424 7434
43. C.A. Spina, J. Anderson, N.M. Archin, A. Bosque, J. Chan, and M. Famiglietti et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients PLoS Pathog 9 2013 e1003834
44. S. Xing, and R.F. Siliciano Targeting HIV latency: Pharmacologic strategies toward eradication Drug Discov Today 18 2013 541 551
45. C. Van Lint, S. Emiliani, M. Ott, and E. Verdin Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation EMBO J 15 1996 1112 1120
46. A.R. Schroder, P. Shinn, H. Chen, C. Berry, J.R. Ecker, and F. Bushman HIV-1 integration in the human genome favors active genes and local hotspots Cell 110 2002 521 529
47. Y. Han, K. Lassen, D. Monie, A.R. Sedaghat, S. Shimoji, and X. Liu et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes J Virol 78 2004 6122 6133
48. G. He, L. Ylisastigui, and D.M. Margolis The regulation of HIV-1 gene expression: the emerging role of chromatin DNA Cell Biol 21 2002 697 705
49. L. Ylisastigui, N.M. Archin, G. Lehrman, R.J. Bosch, and D.M. Margolis Coaxing HIV-1 from resting CD4 T cells: Histone deacetylase inhibition allows latent viral expression AIDS 18 2004 1101 1108
50. N.M. Archin, A. Espeseth, D. Parker, M. Cheema, D. Hazuda, and D.M. Margolis Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid AIDS Res Hum Retroviruses 25 2009 207 212
51. N.M. Archin, A.L. Liberty, A.D. Kashuba, S.K. Choudhary, J.D. Kuruc, and A.M. Crooks et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy Nature 487 2012 482 485
52. N.M. Archin, R. Bateson, M. Tripathy, A.M. Crooks, K.H. Yang, and N.P. Dahl et al. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat J Infect Dis 2014 [Epub ahead of print]
53. J. Blazkova, T.W. Chun, B.W. Belay, D. Murray, J.S. Justement, and E.K. Funk et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy J Infect Dis 206 2012 765 769
54. S.Y. Kao, A.F. Calman, P.A. Luciw, and B.M. Peterlin Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product Nature 330 1987 489 493
55. K. Bartholomeeusen, K. Fujinaga, Y. Xiang, and B.M. Peterlin Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription J Biol Chem 288 2013 14400 14407
56. J. Kulkosky, D.M. Culnan, J. Roman, G. Dornadula, M. Schnell, and M.R. Boyd et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART Blood 98 2001 3006 3015
57. Y.D. Korin, D.G. Brooks, S. Brown, A. Korotzer, and J.A. Zack Effects of prostratin on T-cell activation and human immunodeficiency virus latency J Virol 76 2002 8118 8123
58. D.G. Brooks, D.H. Hamer, P.A. Arlen, L. Gao, G. Bristol, and C.M. Kitchen et al. Molecular characterization, reactivation, and depletion of latent HIV Immunity 19 2003 413 423
59. S.A. Williams, L.F. Chen, H. Kwon, D. Fenard, D. Bisgrove, and E. Verdin et al. Prostratin antagonizes HIV latency by activating NF-kappaB J Biol Chem 279 2004 42008 42017
60. E.J. Beans, D. Fournogerakis, C. Gauntlett, L.V. Heumann, R. Kramer, and M.D. Marsden et al. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo Proc Natl Acad Sci U S A 110 2013 11698 11703
61. C.K. Bullen, G.M. Laird, C.M. Durand, J.D. Siliciano, and R.F. Siliciano New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo Nat Med 20 2014 425 429
62. X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, and P. Deutsch et al. Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117 122
63. D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, and M. Markowitz Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123 126
64. L. Shan, K. Deng, N.S. Shroff, C.M. Durand, S.A. Rabi, and H.C. Yang et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation Immunity 36 2012 491 501
65. P.W. Denton, J.M. Long, S.W. Wietgrefe, C. Sykes, R.A. Spagnuolo, and O.D. Snyder et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART PLoS Pathog 10 2014 e1003872
66. G. Dornadula, H. Zhang, B. VanUitert, J. Stern, L. Livornese Jr., and M.J. Ingerman et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy JAMA 282 1999 1627 1632
67. S. Palmer, A.P. Wiegand, F. Maldarelli, H. Bazmi, J.M. Mican, and M. Polis et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma J Clin Microbiol 41 2003 4531 4536
68. F. Maldarelli, S. Palmer, M.S. King, A. Wiegand, M.A. Polis, and J. Mican et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia PLoS Pathog 3 2007 e46
69. S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein, G.J. Hanna, and S.C. Brun et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy Proc Natl Acad Sci U S A 105 2008 3879 3884
70. Y.C. Ho, L. Shan, N.N. Hosmane, J. Wang, S.B. Laskey, and D.I. Rosenbloom et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure Cell 155 2013 540 551
71. U. O'Doherty, W.J. Swiggard, D. Jeyakumar, D. McGain, and M.H. Malim A sensitive, quantitative assay for human immunodeficiency virus type 1 integration J Virol 76 2002 10942 10950
72. J.J. Yu, T.L. Wu, M.K. Liszewski, J. Dai, W.J. Swiggard, and C. Baytop et al. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients Virology 379 2008 78 86
73. M.C. Strain, and D.D. Richman New assays for monitoring residual HIV burden in effectively treated individuals Curr Opin HIV AIDS 8 2013 106 110
74. S. Eriksson, E.H. Graf, V. Dahl, M.C. Strain, S.A. Yukl, and E.S. Lysenko et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies PLoS Pathog 9 2013 e1003174
75. N.G. Sandler, and D.C. Douek Microbial translocation in HIV infection: causes, consequences and treatment opportunities Nat Rev Microbiol 10 2012 655 666
76. M. Zeng, P.J. Southern, C.S. Reilly, G.J. Beilman, J.G. Chipman, and T.W. Schacker et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy PLoS Pathog 8 2012 e1002437
77. W.S. Post, M. Budoff, L. Kingsley, F.J. Palella Jr., M.D. Witt, and X. Li et al. Associations between HIV infection and subclinical coronary atherosclerosis Ann Intern Med 160 2014 458 467
78. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://Aidsinfo.nih.gov/ contentfiles/lvguidelines/AdultandAdolescentGL.pdf.